Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1839-1848

  Schlesinger, Naomi ^a   Alten, Rieke E ^b   Bardin, Thomas ^c   Schumacher, H Ralph ^d   Bloch, Mark ^e   Gimona, Alberto ^f   Krammer, Gerhard ^f   Murphy, Valda ^f   Richard, Dominik ^f   So, Alexander K ^g  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Holdsworth House Medical Practice   (Australia)

^f NOVARTIS PHARMA AG   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; GAMMA GLUTAMYLTRANSFERASE; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRIAMCINOLONE ACETONIDE; URATE;

ADULT; AGED; ANGINA PECTORIS; AORTA STENOSIS; AORTA VALVE DISEASE; AORTA VALVE REGURGITATION; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; GASTROENTERITIS; GLAUCOMA; GOUT; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INJECTION SITE REACTION; INTERVERTEBRAL DISK HERNIA; JAW ABSCESS; JAW DISEASE; JOINT SWELLING; KIDNEY ARTERY STENOSIS; KNEE MENISCUS RUPTURE; LEUKOCYTE COUNT; LIMB ABSCESS; LIMB DISEASE; LIPID BLOOD LEVEL; LIPOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PANCREATITIS; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SPINAL CORD ISCHEMIA; SPONDYLOLISTHESIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VERTEBRAL CANAL STENOSIS; VERTEBROBASILAR INSUFFICIENCY; VISUAL ANALOG SCALE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, GOUTY; DOUBLE-BLIND METHOD; FEMALE; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867405545     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200908     Document Type: Article

References (46)

1. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
2. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40:37-42. (Pubitemid 34701209)
3. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008;10:221.
4. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005;11(15 Suppl):S443-50; quiz S465-8
5. Schlesinger N. Diagnosis of gout. Minerva Med 2007;98:759-67. (Pubitemid 351196064)
6. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
7. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
9. Neogi T. Clinical practice. Gout. N Engl J Med 2011;364:443-52.
10. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
11. Riedel AA, Nelson M, Wallace K, et al. Prevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care Setting. J Clin Rheumatol 2004;10:308-14. (Pubitemid 39614246)
12. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155-63.
13. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010;69:1907-12.
14. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
15. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009;48:582-6.
16. Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep 2010;12:118-24.
17. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416. (Pubitemid 39480701)
18. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther 2010;12:206.
19. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R67.
20. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
21. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
22. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al.; Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
23. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-17.
24. Neogi T. Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum 2010;62:2845-9.
25. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
26. Cho M, Ghosh P, Hans G, et al. The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients. Arthritis Rheum 2010;62(Suppl 10):S69.
27. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60. (Pubitemid 351736009)
28. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-71.
29. Berger P, McConnell JP, Nunn M, et al. C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 2002;17:171-4.
30. Ilaris (canakinumab) injection (package insert). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009.
31. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011;11:505-18.
32. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev 2011;24:490-7.
33. Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord 2011;12:153.
34. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis 1997;56:696-7.
35. Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002;29:1950-3. (Pubitemid 34988705)
36. Schlesinger N, Baker DG, Schumacher HR Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol 1997;24:2265-6.
37. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol 2009;36:1287-9.
38. Doherty M, Bardin T, Pascual E. International survey on the diagnosis and management of gout. Ann Rheum Dis 2007;66:1685-6. (Pubitemid 350205465)
39. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269-70. (Pubitemid 47492466)
40. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92. (Pubitemid 34666615)
41. Cheng TT, Lai HM, Chiu CK, et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399-406.
42. Kenalog-40 (triamcinolone acetonide) injectable suspension (for intramuscular or intra-articular use only) (package insert). Princeton, NJ: Bristol-Myers Squibb Company, 2011.
43. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606. (Pubitemid 38202232)
44. Pfizer. Celebrex in acute gouty arthritis study. 2011. NCT00549549. http://www.Clinicaltrials.gov (Accessed April 13 2012).
45. Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) 2007;46:1126-32. (Pubitemid 47050616)
46. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.